ReviewMediators of inflammation2015
Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives.
Review in Mediators of inflammation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 30 citations in OpenAlex.
- Treat-to-target in Behçet syndrome.Nature reviews. Rheumatology · 2026Review
- Vascular Behçet's Disease: A Case of Arterial Occlusion and Successful Medical Management.Case reports in medicine · 2026Article
- Candidate Drugs Screening for Behcet's Disease Based on Bioinformatics Analysis and Mouse Experiments.Frontiers in immunology · 2022Article
- Superior vena caval obstruction: a rare presentation of Behcet's disease.BMJ case reports · 2020Article
- Main Oral Manifestations in Immune-Mediated and Inflammatory Rheumatic Diseases.Journal of clinical medicine · 2018Review
- Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease.Clinical rheumatology · 2017Article
- Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study.Clinical rheumatology · 2017Observational
- Behçet's syndrome: providing integrated care.Journal of multidisciplinary healthcare · 2017Review
- Ocular Involvement in Systemic Autoimmune Diseases.Clinical reviews in allergy & immunology · 2015Review
- Off-label use of anti-IL-1 drugs in rheumatic diseases.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Behçet's disease (BD) is a multisystemic disorder of unknown etiology characterized by the "triple symptom complex" consisting of recurrent oral aphthosis, genital ulcers, and chronic relapsing bilateral uveitis. Recurrent mucocutaneous lesions are generally considered the hallmark of the disease, being the most common symptoms presenting at the onset of disease. Although the improvement of knowledge about the pathogenetic mechanism added important changes in the treatment management of BD clinical manifestations, thus avoiding the appearance of serious life-threatening complications which are disease related, the mucocutaneous lesions are still the most nagging clinical manifestations to be treated. In this work we reviewed the current state of knowledge regarding the therapeutic approaches for mucocutaneous lesions of BD mainly based on controlled studies to provide a rational framework for selecting the appropriate therapy for treating these troublesome features of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.